← All themes
Theme

Cannabis

Every analyzed stock in Cannabis — 23 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Cannabis risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
36 /100 Moderate ▼ -6 mild
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
62 /100 High ▲ +9 mild
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 8 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
35 Moderate
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 8 stocks.
41 Elevated
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
31 Moderate
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
45.9%
Moderate
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
36%
Moderate
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
23%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 22 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Cannabis
Cannabis — Sep 7 – Sep 11, 2026 (Wk 37): Cannabis Sector Volatility: Stock Slides and Lender Interest Amidst Mixed Signals →
The cannabis sector experienced notable stock volatility this week, with several companies seeing share price pressure while others delivered returns. This occurred against a backdrop of continued interest from specialized lenders and a focus on rental…
ACB
AURORA CANNABIS INC
Valuation N/A
Healthcare Risk 55 · Elevated
Price$3.82
Model IV—
P/IV—
Limited data — see page
AFCG
Advanced Flower Capital Inc.
Deeply overvalued
Unknown Risk 62 · High
Price$3.50
Model IV$0.92
P/IV4.06
Premium +281% Return to IV: -73.8%
Market implies +10.4%/yr vs model -7.5% · above model
AKAN
AKANDA CORP.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.07
Model IV—
P/IV—
Limited data — see page
BHST
BIOHARVEST SCIENCES INC.
Deeply undervalued
Healthcare Risk 32 · Moderate
Price$1.85
Model IV$9.07
P/IV0.43
Discount 80% Return to IV: +390.2%
Market implies -30.1%/yr vs model +50.0% · below model
BNCWZ
CEA Industries Inc.
Valuation N/A
Basic Materials Risk 31 · Moderate
Price$0.15
Model IV—
P/IV—
Market implies +4.7%/yr vs model +0.0% · above model
CGC
Canopy Growth Corp
Valuation N/A
Healthcare Risk 53 · Elevated
Price$0.94
Model IV—
P/IV—
Limited data — see page
CRON
Cronos Group Inc.
Overvalued
Healthcare Risk 42 · Elevated
Price$3.14
Model IV$2.46
P/IV1.15
Premium +27% Return to IV: -21.5%
Market implies -6.6%/yr vs model +22.8% · below model
GNLN
Greenlane Holdings, Inc.
Valuation N/A
Industrials Risk 42 · Elevated
Price$2.98
Model IV—
P/IV—
Market implies +34.9%/yr vs model +2.0% · above model
GRUSF
Grown Rogue International Inc.
Deeply overvalued
Basic Materials Risk 66 · High
Price$0.44
Model IV$0.09
P/IV4.92
Premium +371% Return to IV: -78.7%
Market implies +25.0%/yr vs model +5.0% · above model
HITI
High Tide Inc.
Valuation N/A
Consumer Cyclical Risk 36 · Moderate
Price$2.53
Model IV—
P/IV—
Limited data — see page
HYFM
HYDROFARM HOLDINGS GROUP, INC.
Valuation N/A
Consumer Defensive Risk 64 · High
Price$0.98
Model IV—
P/IV—
Market implies -45.7%/yr vs model +2.0% · below model
IIPR
INNOVATIVE INDUSTRIAL PROPERTIES INC
Deeply undervalued
Real Estate Risk 34 · Moderate
Price$56.25
Model IV$126.33
P/IV0.46
Discount 55% Return to IV: +124.6%
Market implies -6.7%/yr vs model +6.0% · below model
IMCC
IM Cannabis Corp.
Valuation N/A
Healthcare Risk 49 · Elevated
Price$1.75
Model IV—
P/IV—
Limited data — see page
INCR
Intercure Ltd.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$5.16
Model IV—
P/IV—
Limited data — see page
ISPR
Ispire Technology Inc.
Deeply overvalued
Consumer Defensive Risk 38 · Moderate
Price$1.44
Model IV$0.71
P/IV2.02
Premium +102% Return to IV: -50.4%
Market implies +6.8%/yr vs model +2.2% · above model
OGI
ORGANIGRAM GLOBAL INC.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$1.05
Model IV—
P/IV—
Limited data — see page
REFI
Chicago Atlantic Real Estate Finance, Inc.
Deeply undervalued
Financial Services Risk 25 · Moderate
Price$10.73
Model IV$34.42
P/IV0.33
Discount 69% Return to IV: +220.8%
SNDL
SNDL Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$1.34
Model IV—
P/IV—
Limited data — see page
TLRY
Tilray Brands, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$4.02
Model IV—
P/IV—
Market implies +29.1%/yr vs model +12.5% · above model
UGRO
urban-gro, Inc.
Valuation N/A
Industrials Risk 36 · Moderate
Price$1.18
Model IV—
P/IV—
Market implies -44.9%/yr vs model +2.0% · below model
VFF
Village Farms International, Inc.
Valuation N/A
Basic Materials Risk 40 · Elevated
Price$2.88
Model IV—
P/IV—
Market implies +37.8%/yr vs model +0.0% · above model
XXII
22nd Century Group, Inc.
Valuation N/A
Consumer Defensive Risk 33 · Moderate
Price$1.99
Model IV—
P/IV—
Market implies -30.0%/yr vs model +2.0% · below model
YCBD
cbdMD, Inc.
Deeply undervalued
Consumer Defensive Risk 29 · Moderate
Price$0.46
Model IV$2.09
P/IV0.38
Discount 78% Return to IV: +353.2%
Market implies -34.4%/yr vs model +2.0% · below model